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Abstract
Takotsubo syndrome, or previously named as Takotsubo cardiomyopathy, is an increa- 
singly recognized acute reversible form of heart failure, which is typically seen in post-
menopausal women following emotional or physical stress. Although several mecha-
nisms regarding pathophysiology had been proposed, the most common ones include 
catecholamine toxicity, diffuse epicardial coronary artery spasm and microvascular dys-
function. A vast majority of patients with TTS (>90%) have good prognosis as they regain 
normal left ventricular systolic function in 3–6 months after the acute phase. Increased 
awareness among physicians led to the recognition of a great number and variety of 
conditions associated with TTS and played a key role for the development of new diag-
nostic criteria. However, there are still big gaps in the management and treatment of this 
syndrome to be supported with further well-designed randomized controlled trials.
Keywords: Takotsubo syndrome, Takotsubo cardiomyopathy, apical ballooning 
syndrome, brokenheart syndrome, stress cardiomyopathy
1. Introduction
When Sato et al. [1] first described Takotsubo Cardiomyopathy (TTC) 28 years ago, they were 
probably unaware of carrying out a new area of debates in daily cardiology practice. The 
name “Takotsubo” was inspired from a Japanese octopus trap used by Japanese fisherman.
To date, more than 75 names were used for description of TTC in the literature with the most 
commonly used three names include Takotsubo cardiomyopathy, Takotsubo syndrome and apical 
ballooning syndrome [2]. ‘Broken heart syndrome’ definition was used in sarcasm to emphasize 
the close relationship between disease and stressful triggers; however, joyful incidents have 
also been shown to be associated with TTC thus called ‘happy heart syndrome’ [3].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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Although diagnostic criteria of TTC were described long ago, recent debates focus on defi-
nition (rather than treatment) whether this form of heart failure is a cardiomyopathy or a 
syndrome [4]. Growing body of evidence including diseases, conditions, toxins or drugs 
associated with Takotsubo Syndrome (TTS) has provided a wide insight into disease patho-
physiology. The authors favoring the use of TTS save the idea that patients with TTS suffer 
severe myocardial ischemia and show most of the indirect signs of ischemia (ECG changes, 
troponin rise, chest pain and wall motion abnormalities). The mechanism underlying TTS 
can not be solely explained with ischemia and vascular impairment via contemporary data. 
Nonetheless, Redfors et al. [5] demonstrated that myocardial perfusion at TTS onset is normal 
despite increased catecholamine levels. The definition of cardiomyopathy defined as ‘myo-
cardial disorder in which the heart muscle is structurally of functionally abnormal in the absence 
of coronary artery disease, hypertension, valvular disease and congenital heart disease sufficient to 
explain the observed myocardial abnormality’ qualifies and covers TTS as a cardiomyopathy but 
several controversial subjects need to addressed such as (1) transient nature of the disease, 
(2) lack of genetic origin, (3) presence of certain trigger factors, (4) close relationship with 
catecolamine excess, (5) lack of macroscobic fibrosis or significant necrosis in histopathologi-
cal examination, (6) presence of intense myocardial edema in the acute phase of TTS. On the 
other hand, current evidence is not consistent with the authors suggesting classification of 
TTS in the context of acute coronary syndromes [4].
The most recent comprehensive assessment of TTS was performed in a position statement 
by European Society of Cardiology (ESC) which suggested the use of TTS definition instead 
of TTC. Therefore, it makes more sense to use TTS instead of cardiomyopathy in consistence 
with current data and ESC recommendations. Moreover, they subdivided TTS into primary 
and secondary forms [6].
The main characteristics of TTC include chest pain associated with ECG changes, which 
mimic ACS, transient left ventricular systolic dysfunction, modest elevated levels of cardiac 
troponin and the absence of obstructive coronary artery disease documented by coronary 
angiography [7].
It is hard to say that increased number and variety of case reports have contributed to a 
completely clear understanding of this disease. Just think of a disease that can be associated 
with coronary ischemia, heart failure, arrhythmia, sudden death and also usually transient 
and in benign nature. When all components of this syndrome are taken into account, a mul-
tidisciplinary approach and additional research in the context of etiology, pathophysiology, 
triggering factors and optimal treatment seem essential for better understanding.
2. Epidemiology
Although the exact incidence of TTs is not known, increasing number of case reports and asso-
ciated conditions are added into the literature. In an European cohort, TTs were reported to be 
responsible for 1.7% of admissions for acute coronary syndrome and to have an incidence of 
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0.3% for all coronary angiographies [8]. Another study investigating the prevalence of TTS in 
the United States examined more than 33 million hospitalizations and found an incidence of 
6837 (0.02%) patients with a diagnosis of TTs [9]. The majority of the patients were aged from 
65 to 79 (43.2%) and women (90.4%). Women older than 55 years of age were at nearly fivefold 
increased risk of developing TTS than women <55 years old [10]. The real prevalence of TTs is 
assumed to be underestimated owing to lack of widespread access to coronary angiography 
and detailed postmortem examination of patients with fatal arrhythmias and sudden cardiac 
death. The International Takotsubo Registry (InterTAK Registry) has been the largest study 
cohort of patients with TTS which included 1750 cases from 26 centers in Europe and United 
States [11]. Although full results have not been published yet and contemporary information 
about the prevalence of TTS was not available, it was interesting to find that 15.3% of patients 
with TTS had evidence of concomitant coronary artery disease (CAD) in contrast with the 
common belief that exclusion of CAD is necessary to establish TTS diagnosis.
3. Triggering factors
In contrast with the common belief of close relationship with emotional triggers (broken-
heart syndrome), InterTAK registry demonstrated that physical triggers were more common 
than emotional triggers (36 vs. 27.7%) while the remainder had no obvious triggering factor. 
Furthermore, physical triggers were found to be an independent predictor for in-hospital 
complications [3].
The most common emotional triggers include death of a first-degree relative, severe fear or 
anger episodes, anxiety disorders, financial or legal matters and less frequently (less than 
10%) joyful events such as birthday parties or weddings. Physical triggers are events mostly 
associated with catecolamine surge including cases of stroke, subarachnoid hemorrhage, sur-
gery, malignancy, drug abuse, psychiatric illness, and so on.
History of a neurologic or psychiatric disorder was detected in more than half of the patients 
with TTS in the InterTAK registry [3]. The same registry also revealed age and the presence 
of emotional triggers as protective from in-hospital complications. One-third of patients with 
sub-arachnoid hemorrhage has TTS [12].
4. Pathophysiology
The relationship between triggering factors and TTS naturally caused accusation of catecola-
mine excess in the pathogenesis of TTS [13]. Although catecolamine excess hypothesis in TTS 
was supported by several times higher concentrations of plasma catecholamines including epi-
nephrine, norepinephrine and dopamin in the acute phase of TTS when compared with levels 
in STEMI and also increased local myocardial release of catecholamine, benefit of b-blockers 
were derived from trials including patients with heart failure rather than patients with TTS [14].
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Another evidence favoring the authors suggesting use of ‘Takotsubo syndrome’ instead of car-
diomyopathy definition is the common existence of endothelial dysfunction in patients with 
TTS. Myocardial ischemia caused by vasospasm which is triggered by stress and increased 
catecolamines in coronary vasculature with endothelial dysfunction represents a reasonable 
cascade of pathophysiology underlying TTS. However, further studies are needed to elicit 
the role of endothelial dysfunction in TTS as just one of the contributing factors or an essen-
tial component. Epicardial coronary spasm was demonstrated in only 20% of patients with 
TTS in two different studies and confirmed by acetylcholine testing in another study [7, 15]. 
Spontaneous coronary artery dissection and coronary microvascular dysfunction were the 
other postulated mechanisms responsible for TTS. Reversible coronary microvascular dys-
function was demonstrated by transient improvement in perfusion defects after infusion of 
intracoronary adenosine and complete recovery 1 month later [15]. In the postmenopausal 
period, reduced levels of estrogen end up with increased sympathetic tonus and endothelial 
dysfunction. When combined with age and the common prevalence of classical risk factors for 
cardiovascular disease in the typical postmenopausal woman patient profile of TTS, additive 
effect of increased catecholamines (direct toxicity via circulation or nerve terminals), reduced 
estrogen levels and endothelial dysfunctions should be considered.
The pattern of LV dysfunction in TTS (apical ballooning) was subject to a great number of 
studies. Increased expression of β2-adrenoreceptors in apical segments than basal segments of left ventricle was shown in animal studies whereas norepinephrine β
1
-adrenoreceptors 
had reverse distribution. This finding was supported by a rat model treated with high-dose 
epinephrine bolus (to mimic catecolamine storm) culminating in apical myocardial depres-
sion and basal hypercontractile response. Lack of the same response with equivalent bolus of 
norepinephrine suggested an epinephrine-specific response [5]. Another hypothesis pro-




Endothelial dysfunction (±reduced estrogen levels)
Coronary microvascular dysfunction
Obstruction of left ventricular outflow tract
Spotaneous coronary artery dissection
Transient metabolic disorder on the cellular level
Sudden increase in ventricular afterload
Aborted myocardial infarction with spontaneous recanalization
Myocardial bridging and myocardial edema
Table 1. Mechanisms proposed for the pathophysiology of Takotsubo syndrome.
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shutting down contractile apparatus in certain segments of LV and maintenance of vital 
functions [5]. Actually, this mechanism might be favored for mechanisms responsible for 
recovery process and was supported by a study demonstrating same cell survival signal-
ing pathways of ischemic preconditioned tissue in biopsies obtained from patients with 
TTS [16]. The authors from the same study also suggested that transient LV outflow tract 
obstruction (stimulated by isoprenaline—strong adrenergic stimulus) occurs when LV 
contracts too forcefully and leads to a pressure gradient between the apex and the aorta 
thus raising wall tension in regions located more apical than the obstruction [5]. Recent 
studies employed with nuclear medicine techniques suggested that a transient metabolic 
disorder on the cellular level is responsible for apical ballooning rather than an impairment 
in myocardial contractile structure which may be associated with interruption of glucose 
metabolism via coronary microcirculation. A list of proposed mechanisms involved in the 
pathophysiology of TTS is shown in Table 1.
5. Patient evaluation
5.1. History
The most common symptom in patients presenting with TTS is chest pain (75%) as seen in 
acute coronary syndromes. The nature of the pain is not specific, thus not helpful in dif-
ferential diagnosis. The following chief symptom is dyspnea (47%). When the high rate 
(87%) of patients having reduced LV ejection fraction (EF) in the setting of TTS is taken into 
account, less than half of the patients (47%) presenting with dyspnea may seem relatively low. 
Nevertheless, this discrepancy is supported by the fact that patients with TTS frequently have 
a benign course despite losing >50% functional left ventricular myocardium while a patient 
with ACS faces death in loss of a similar sized portion of LV myocardium [5, 17]. Nonetheless, 
it should be noted that in-hospital death rates are similar between patients with TTS and 
ACS. Syncope, cardiac arrest, cardiogenic shock and ventricular arrhythmias are much less 
common symptoms but should be kept in mind. These symptoms are more likely to occur 
with less common clinical subtypes other than apical ballooning. Reverse (inverted) TTS was 
shown to present at a younger age and with fatal ventricular arrhythmias [18].
5.2. Laboratory
Troponin levels are elevated in the vast majority of patients with TTS; however, the severity of 
elevation is not helpful for discriminating between acute coronary syndromes. Nonetheless, 
InterTAK registry significant differences in increased troponin levels between patients with 
TTS and ACS (1.8 vs. 6, p < 0.001). A first troponin measurement of more than 10 times of 
the upper limit of normal level was deemed as a poor prognostic factor. On the other hand, 
brain natriuretic levels were almost six times higher in patients with TTS than patients 
with ACS. When compared with ACS, troponin levels in TTS are lower. Acute ventricular 
insult in left ventricle triggers stretching and release of neuroendocrine peptides such as 
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brain-natriuretic peptide (BNP). Levels of NT-proBNP were more than twofold higher in 
patients with TTS than patients with STEMI (4702 vs. 2138 pg/ml, respectively) in a recent 
study [19].
Several reports investigating the use of other biomarkers in TTS detected elevations in serum 
catecolamine, neuropeptide, serotonin, carbonhydrate-antigen 125 levels but none of them 
is preferred in daily practice. Further research is required for established utilization of those 
biomarkers.
5.3. Electrocardiography
TTS can present with various changes on electrocardiography. Although the most common 
presentation includes ST-segment elevation and/or T-wave inversion, several new electrocar-
diographic alterations including QT-prolongation, attenuation of QRS complexes, new bun-
dle-branch blocks or ventricular arrhythmias have been defined [20]. It should be noted that 
the timing of medical contact is important for detection of ECG changes since it is a pathologi-
cal process. QT prolongation is one of the distinct features from STEMI; however, differential 
diagnosis should not be based on ECG basis in particular ST-elevation in TTS. Typical exten-
sion of left ventricle dysfunction beyond the vascular territory of a single epicardial coronary 
artery is one of the key features of TTS.
5.4. Echocardiography
Transthoracic echocardiography is the primary choice of noninvasive imaging method due to 
its widespread and practical utility for patients with suspected TTS.
TTS with apical involvement is the most common type (82%) followed with mid-ventricular, 
basal and focal type in decreasing frequency. Typical findings suggesting TTS include regional 
wall motion abnormality (mostly apical akinesia and basal hyperkinesia) extending beyond 
the territory of a certain epicardial coronary artery. End-diastolic diameter measured from 
the mid-ventricular plane is increased and measurement of EF is usually under 45%. Sudden 
insult in LV systolic function often leads to mitral regurgitation. Imbalance of wall pressure 
between akinetic and hyperkinetic segments within the cavity might develop left ventricle 
outflow tract obstruction (pressure gradient, acceleration of blood flow) in some patients.
Follow-up of patients with TTC by serial echocardiographic examinations demonstrated 
noticeable recovery in systolic left ventricular function. Naturally, a LVEF <45% is a predictor 
of a worse prognosis [6, 20].
5.5. Cardiac magnetic resonance imaging
When the clinical presentation of TTS in the acute phase is considered, cardiac magnetic 
resonance imaging (cMRI) is not suitable for initial evaluation. After documentation of 
normal or near-normal coronary arteries with coronary angiography, cMRI is the pre-
ferred imaging method for its complementary data about three-dimensional LV and RV 
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anatomy,documentation of regional wall motion abnormality thus TTS subtypes (apical, mid-
ventricular, inverted or focal). Diffuse myocardial edema is typically present in both myocar-
ditis and TTS; however, lack of late gadolinium enhancement in TTS is helpful for differential 
diagnosis from both acute coronary syndrome an acute myocarditis. Though not standard, 
common practice for timing of cMRI is within 7 days after the index event and 2–6 months 
later for assessment of improvement in systolic functions [19].
5.6. Coronary angiography
Presentation of patients with chest pain and frequently ST-elevation leads the patients undergo 
coronary angiography even though TTS is not the diagnosis in the first place. Detection of 
normal or near-normal coronary arteries should suggest TTS and the operator should per-
form left ventriculography for the typical appearance of left ventricular apical ballooning.
Similarly, a great portion of patients with TTS (93%) had increased LV end-diastolic pressure 
(>11 mm) on angiography in the InterTAK registry.
Mayo Clinical criteria included normal or near-normal coronary angiography for establish-
ment of TTS diagnosis; however, InterTAK registry documented by coronary angiography 
that coronary artery disease was present in 15% of patients with TTS. Coronary angiography 
remains to be the major method for distinguishing TTS from ACS in spite of increasing non-
invasive modalities.
5.7. Diagnosis
Although a definition accepted worldwide does not exist, the most common one used for a 
long time in daily practice and research area included The Mayo Clinic diagnostic criteria 
which were modified in 2008; (1) transient hypokinesis, akinesis, or dyskinesis of the left 
ventricular mid-segments with or without apical involvement; the regional wall motion 
abnormalities extend beyond a single epicardial vascular distribution; a stressful trigger 
is often, but not always present; (2) the absence of obstructive coronary disease or angio-
graphic evidence of acute plaque rupture; (3) new electrocardiographic abnormalities (either 
ST-segment elevation and/or T-wave inversion) or modest elevation in cardiac troponins; (4) 
the absence of pheocromocytoma or myocarditis. In 2016, a position statement on TTS pub-
lished by European Heart Failure Association (EHFA) taskforce updated diagnostic criteria as 
shown in Table 2 [6].
Addition of ‘reversible’ expression for ECG abnormalities and QTc prolongation, replacement 
of mild with significant for elevation of serum natriuretic peptides, removal of exclusion of 
pheochromocytoma and addition of recovery of ventricular function in 3–6 months are the 
first noticeable changes in the EHFA criteria.
Unlike the post-menopausal women profile of classical type, reverse type was shown to be 
significantly associated with younger age and mental or physical stress rather than cateco-
lamine excess [11, 18]. Of note, death was more common in men than women with TTS [11].




Although TTC is assumed to have a benign course in general, InterTAK registry reported 
the rate of death as 5.6% per patient-year. Patients with TTC may develop recurrence even 
after years [11]. Furthermore, the rate of serious in-hospital complications (21%) similar to 
that in ACS should make us question the commonly recognized benign course of the study. 
The rate of major adverse cardiac and cerebrovascular events including death, stroke/TIA in 
the first month of admission was 7.1%. Major complications include acute heart failure and 
cardiogenic shock, LV outflow tract obstruction, severe mitral regurgitation, fatal ventricular 
arrhythmias, thrombus in the akinetic segments of the ventricle. Predictors of poor prognosis 
include LV EF < 35%, RV involvement, QTc > 500 ms, BNP > 600 pg/ml, age < 75 years, car-
diogenic shock and ventricular arrhythmias. Nevertheless, the prognosis is good for more 
than 90% of the patients as they regain normal systolic function in 3–6 months after the acute 
episode [19, 21].
6.1. Treatment
There are no randomized controlled trials to evaluate the efficacy of a certain treatment but 
retrospective analysis of outcomes reveals improved survival at 1 year with the use of angio-
tensin-converting-enzyme inhibitors or angiontensin-receptor blockers. Current approach 
includes a combination of evidence-based acute coronary syndrome and heart failure treat-
ments [6]. Interestingly, in spite of either the ascribed role of catecolamine excess in the 
pathophysiology of TTC and the left ventricular systolic dysfunction, beta-blocker use was 
not associated with improved mortality at 1 year. However, retrospective and observational 
nature of the analysis should always be kept in mind, and further studies with prospective 
design are needed to obtain more accurate and reliable results. Symptoms of heart failure 
(1) Transient regional wall motion abnormalities of LV (or RV) myocardium which are frequently but not always 
preceded by stressful trigger (emotional or physical)
(2) The regional wall motion abnormality usually (exceptions reported) extends beyond a single epicardial vascular 
distribution and often results in circumferential dysfunction of the ventricular segment involved
(3) New and reversible ECG abnormalities (ST segment elevation, ST depression, LBBB, T wave inversion and/or 
QTc prolongation in acute phase)
(4) Significant elevation of serum natriuretic peptide (BNP or NT-proBNP) during acute phase.
(5) Positive but relatively small elevation of cardiac troponin measured with a conventional assay (troponinnegative 
cases have been reported)
(6) Absence of culprit atherosclerotic disease including plaque rupture, thrombus formation and coronary dissection 
or other pathological conditions to explain the pattern of temporary LV Dysfunction,for example, hypertrophic 
cardiomyopathy, viral myocarditis, and so on
(7) Recovery of ventricular function on cardiac imaging on follow-up (3–6 months).
Table 2. European heart failure association (EHFA) taskforce updated diagnostic criteria.
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must be closely monitored and treated and also the physician should be alert for ventricular 
arrhythmias during the acute phase. The risk tends to incline in time but is always present 
until complete recovery of LV systolic function [6].
Treatment of the patients should be categorized in two titles under acute phase and follow-
up period. The risk is the highest in the acute phase so the patients should be monitored 
in coronary care unit with the capabilities of urgent coronary angiography, temporary and 
permanent pacemaker implantation, ventricular arrhythmia management and advanced 
heart failure therapy including LV assist devices and extra-corporeal membrane oxygen-
ation (ECMO). In patients with cardiogenic shock, sympathomimetic agents should be 
avoided. Levosimendan might be a useful option in cardiogenic shock despite limited evi-
dence [22]. Standard heart failure therapy should be implemented in patients with signs 
of congestion. In a series of 93 patients with TTS, incidence of ventricular fibrillation or 
Torsades de Pointes (TdP) was 8.6% [23]. Prolongation of QTc > 500 ms is commonly seen 
in patients with low heart rates, so temporary pacemaker may be life-saving for TdP epi-
sodes. Hypomagnesemia and hypokalemia should be checked and corrected as well [19]. 
ICD therapy should be reserved for patients without recovery of LV systolic function or 
recurrent ventricular arrhythmias. Notably, wearable defibrillators might be a good option 
during the acute phase.
During the follow-up period, more than 90% of the patients regain normal LV systolic func-
tion in 4–8 weeks. InterTAK registry found recurrence rate as 1.8% per year [3]. In order to 
prevent recurrences, beta-blockers were the most studied group with ACE inhibitors. In a 
recent meta-analysis by Brunetti et al. none of the therapies including beta-blockers, ACE 
inhibitors, angiotensin-receptor blockers, aspirin and statins were found effective in the pre-
vention of recurrence of TTS [24]. Another recent regression meta-analysis found ACEI useful 
for prevention of recurrence [25]. Randomized controlled trials are awaited for more accurate 
and definitive results.
7. Future directions
Associated conditions helped better understanding of the mechanisms underlying TTS; 
however, mechanisms playing role in the recovery process remain largely elusive. It is obvi-
ous that randomized-controlled studies are needed to have a more clear aspect for standard 
therapy. The role of estrogen and progesterone in the pathophysiology of TTS should be 
addressed by basic scientists and clinicians. Optimal timing and treatment of patients suf-
fering ventricular arrhythmias with ICD (subcutaneous/wearable defibrillator) is not clear 
and well-studied. The pathogenesis and treatment of TTS are still speculative and the risks of 
complications in the acute phase are underestimated. Given the variety of associated condi-
tions and increased number of case reports, international data collection by registries like 
InterTAK registry should be employed and shared for a better understanding and optimal 
treatment.
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